

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

NCT05938712

Status	RECRUITING
Phase	Phase 2
Sponsor	University Health Network, Toronto
Enrollment	20 participants

Plain Language Summary

This study is testing a combination of two diabetes/weight-loss medications — an SGLT2 inhibitor and a GLP-1 receptor agonist — to see if they can improve kidney function, blood sugar control, and weight in kidney transplant recipients.

****You may be eligible if...****

- You are 18 or older and have received a kidney transplant
- It has been more than 3 months since your transplant
- Your kidney is functioning at a moderate level (eGFR at least 20 ml/min)
- Your blood pressure is within a manageable range
- Your BMI is between 18.5 and 40 kg/m²
- You have type 2 diabetes or are overweight with additional risk factors

****You may NOT be eligible if...****

- You have type 1 diabetes
- You have very poor kidney function
- You have had recent serious infections or other transplant complications
- You are pregnant or planning to become pregnant
- You have had recurrent urinary tract infections

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (7)

- Signed and dated written informed consent.
- Patients aged e18 years with KTR
- \>3 months post kidney transplantation
- Estimated glomerular filtration rate [eGFR] e20 ml/min/1.73m²
- BP \<160/100 and \>90/60 at screening
- ... and 2 more (see full listing online)

Exclusion (18)

- Type 1 diabetes.
- History of multi-organ transplant
- Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
- Impending need for kidney biopsy or rapid decline in eGFR within 30 days prior to screening
- Actively treated BK, CMV or EBV infection

<https://clinicaltrials.gov/study/NCT05938712>
... and 13 more (see full listing online)

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).

Locations (1 total)

Toronto General Hospital, Toronto, Ontario, Canada